India is said to be leading in the global pharmaceutical field because it sells affordable medical solutions, even though it is having to face many lawsuits and pressure over intellectual property rules from abroad. The dispute between the need for new medicines and the ability of people to access them is as old as patent laws, yet Novartis vs. India and the WTO show that finding the right solutions can be challenging.
Table of Contents
The Gleevec Precedent: A Defining Legal Showdown
In 2013, the Supreme Court of India came up with a landmark ruling when it ruled against Swiss pharmaceutical giant Novartis for its request for a patent for Gleevec, a life saving antileukemic drug. The improved version of Gleevec did not fulfil the criteria of “novelty” under Section 3(d) of India’s Patent Act and the court ruled in favour of the state government. This clause is unique to India cheque “evergreening” i.e., the practice of making small alterations to currently existing drugs to prolong life of the patent.
The defeat suffered by Novartis was a huge triumph for public health supporters and generics manufacturers. Indian pharma firms made cheaper versions of the drug costing only ₹8,000–₹10,000, whereas the approximate amount of the drug was ₹1.2 lakh per month. The decision did not only reinforce India’s position on affordable healthcare, but it also created a legal precedent that is still guiding patent rulings to date.
However, this position was at a diplomatic and economic cost. India’s IP regime came under criticism from multinational pharma companies saying that it was unpredictable and not investor-friendly. Other governments, especially in the West, started lobbying with the help of trade deals and international organisations against India and towards stricter patent protection.
The WTO Arena: A Tension-Filled Battlefield
The IP rights position of India has been at loggerheads with the developed countries such as the U.S and EU who have always advocated for firm patent enforcement. India being a part of the WTO (World Trade Organisation) and also having signed the TRIPS agreement (Trade-Related Aspects of Intellectual Property Rights), is subject to international commitment. However, India has been adept in utilising flexibilities within TRIPS such as compulsory licensing and Section 3(d) – to protect access to essential medications.
One of such was India’s move in 2012 to issue a compulsory licence for Bayer’s cancer drug Nexavar, allowing a local firm to sell the medicine at a fraction of the price. The step provoked a worldwide discussion, but confirmed the stance of India that life-saving drugs should be available, particularly in low- and medium-income countries.
This friction is a recurrent topic of WTO negotiations, the most recent example of which is the COVID-19 pandemic. India together with South Africa called for a TRIPS waiver in holding off IP rights on vaccines and treatments for a while. Although the proposal got massive support from developing countries, it received stiff opposition from rich nations and pharmaceuticals groups, showing the gulf of patent protection in the global arena against public health.
Generics and the Global South: A Pillar of Public Health
India produces over 20% of the world’s generic medicines because of its 50 + billion dollar pharmaceutical system. From treatments for HIV/AIDS to TB medicines, Indian generics are critical to health programmes around Africa, Asia and Latin America. This function became all the more important during the COVID-19 crisis when India increased production of vaccines and therapeutics.
The low cost manufacturing ecosystem, the talented work force and the regulatory framework provide the country with a competitive advantage. Yet, this leadership is also what India’s assertive patent position allows. By withstanding the impulse to adopt wholesale the IP norms of the West, India has safeguarded its own domestic generic business practices and contributed to making drugs cheaper beyond its borders.
However, this benefit is being threatened. Free trade agreements (FTAs) with Europe or any other parties carry in many cases TRIPS-plus add-ons: calls for data exclusivity, longer patent duration and stricter IP enforcement that can strangle generics. India has to walk on eggshells lest it undermines its public health duties.
The Path Ahead: Balancing Innovation with Access
According to the critics, India’s IP system de-motivates innovation hence America’s R&D companies investing for global pharma companies are discouraged. There is a grain of truth in this fear – India needs domestic ingenuity, not just production power. Nevertheless, there should be no expense of affordability, particularly for vital and life saving drugs.
Perhaps, a middle way would consist in public private partnerships, open source pharma models, and R&D incentives supported by the state. India can rise not only as a generator of generics, but can be a centre of cost effective pharmaceutical innovations. While at it, it also needs to keep its legal weapons at the ready to protect public goods if the need arises, its Section 3(d) and compulsory licensing among such defenders.
A Global Leadership Role on Health Justice
India’s position in patent wars is not a mere trade matter; it is a moral and strategic matter. India has thus become a world leader in health justice following its support of access over monopoly. The task now is to evolve this legacy but by investing in domestic innovation, diplomatically engaging in the global platforms, and making sure that patents work for people and not profit.
